JADPRO (@JADPRO) header
JADPRO (@JADPRO) profile picture

JADPRO

@JADPRO

The Journal of the Advanced Practitioner in Oncology is the first journal developed by and for oncology advanced practitioners.

 Huntington, NY
advancedpractitioner.com
Joined December 2009
  • Tweets3.2K
  • Following1.1K
  • Followers1.3K
1KMedia
Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)Photo by JADPRO (@JADPRO)
Struggling to remember all the cardiotoxicities of cancer therapies? 🩸 #MedTwitter #CardioTwitter #OncTwitter Fam, we’ve got you covered! 👌 Introducing CardsOnc.org 🎗️🫀– 1/9🧵
Image from Sara Diaz Saravia MD (@Sarajdiaz1)
1
14
3
44
14,050
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by @US_FDA 1. #Tepotinib 2. #Osimertinib x2 3. #Alectinib 4. #Tarlatamab 5. #Zenocutuzumab 6. #Durvalumab x2 7. #Amivantamab x2 8. #Nivolumab 9. #Ensartinib #lcsm #OncTwitter #MedTwitter
Image from Oncology Brothers (@OncBrothers)
3
87
8
231
64,880
END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO @ProfCUBlankNKI nejm.org/doi/full/10.1056/NE…
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
9
206
6
653
111,312
My Top Lung Cancer Trials of 2024 #LCSM @OncoAlert @BTFCancerNews Happy New Year !!! 1. LAURA: In this phase-3 trial, pts with unresectable EGFR-mutated stage III NSCLC were randomized to osimertinib or placebo post chemo-RT ➡️↑ PFS with Osimertinib bit.ly/4iZGUXt
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC | NEJM

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC | NEJM

Osimertinib is a recommended treatment for advanced non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated N...

nejm.org
4
39
120
14,852
Immune system
Image from Oren Gottfried, MD (@OGdukeneurosurg)
3
310
7
1,416
169,256
Current recommendation for HPV vaccination and screening of cervical cancer. Taken from Review in @NEJM
Image from Dr Amol Akhade (@SuyogCancer)
1
60
159
22,180
1/ Easily the most provocative #MMsm oral abstract of #ASH24 🤔 Does transplantation interfere with subsequent CAR-T efficacy? Gustine et al @andrew02114 @NoopurRajeMD Part 1 - setting the stage Why high-dose melphalan might interfere with T-cell fitness…
Image from Rahul Banerjee, MD, FACP (@RahulBanerjeeMD)
Image from Rahul Banerjee, MD, FACP (@RahulBanerjeeMD)
Image from Rahul Banerjee, MD, FACP (@RahulBanerjeeMD)
Image from Rahul Banerjee, MD, FACP (@RahulBanerjeeMD)
5
22
4
64
15,215
HCC 101! For the longest time, HCC was a bit of a blackbox to me. So for today’s ROVER presentation, I started off with a 5-slide summary of HCC basics: a 20,000 foot overview. Sharing here. Short thread 🧵 1/6.
Image from Dr. Nina Niu Sanford (@NiuSanford)
9
131
5
394
80,063
#ASH24 @ASH_hematology #mmsm Factors for Individualizing Treatment in Myeloma Care
Image from Samer Al Hadidi, MD,MS,FACP (@HadidiSamer)
1
15
40
4,095
FDA-approved EGFR inhibitors in lung cancer! #LungCancer #EGFR #Oncology @OncoAlert @AACR @IASLC
Image from Yüksel Ürün (@DrYukselUrun)
2
73
1
224
23,764
#ASH24 @ASH_hematology #mmsm BCMA BsAb summary table with some biological differences
Image from Samer Al Hadidi, MD,MS,FACP (@HadidiSamer)
1
22
76
9,903
My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.
Image from Vincent Rajkumar (@VincentRK)
3
120
3
337
46,725
Congratulations to Marlee Bogema, MSN, APRN, FNP-C, for winning JADPRO best poster award! Oral presentation! #JADPROLIVE #APSHO
Image from wendy vogel (@whvogel)
2
5
243
We are at #JADPROLive, the @APSHOorg Annual Meeting! Visit us at Booth #517 and learn about our mission to positively impact patient lives and defeat cancer. More about this event can be found here: jadprolive.com/#BelieversInT… #BelieversInPatients
1
7
312
🧮First-line chemotherapies in advanced pancreatic cancer @TheLancetOncol ✅Meta-analysis reaffirms NALIRIFOX /FOLFIRINOX as first-line regimens @TheLancet @OncoAlert @realbowtiedoc #cancer #oncology #MedX
Image from Erman Akkus (@Erman_Akkus)
Image from Erman Akkus (@Erman_Akkus)
Image from Erman Akkus (@Erman_Akkus)
4
53
2
149
18,700
📢 The @ASCO has released updated living guidelines for treating stage IV #NSCLC with driver alterations! Check out the new recommendations here: ascopubs.org/doi/10.1200/JCO…. With the rapidly evolving, complex treatment algorithms, this guideline is critical! It was an honor to serve on this panel alongside exceptional experts who are all dedicated to providing the most up-to-date, evidence-based guidance to oncology professionals and patients. #LCSM #LCAM #lungcancer #OncoAlert
Image from Jill Feldman (@jillfeldman4)
Image from Jill Feldman (@jillfeldman4)
Image from Jill Feldman (@jillfeldman4)
1
45
2
100
7,120
Planning to join other advanced oncology practitioners at #JADPROLive, November 14-17? Visit booth #1025 to talk with our team of advanced practice providers about the latest innovations in #CancerCare. Register: jadprolive.com/
Image from Guardant Health (@GuardantHealth)
1
2
360
JADPRO retweeted
APSHO (@APSHOorg) profile picture
APSHO@APSHOorg7 Nov 2024
Attention #APSHO Members! Join us at the APSHO Annual Member Meeting during JADPRO Live, November 14, 5-5:45 pm CT. Here is a message from APSHO Vice President Andy Guinigundo about the meeting. Register > jadprolive.com/registration #APSHO #JADPROLive
1
5
89
Our satellite symposium on groundbreaking ADC treatments for NSCLC is almost here! Join us in Grapevine, TX for #JADPROLive as @susanscottmd and Sarah Sagorsky discuss HER2, TROP2, and HER3-targeted therapies. Don’t miss out—register today! 👉bit.ly/3UeDoOl #NSCLC #ADCs
Image from AnswersinCME (@AnswersinCME)
1
1
93
We are excited to be attending JADPRO LIVE 2024! Stop by our booth to meet with our talent partners as well as providers from @utswcancer to learn more about opportunities available to you as an advanced practice provider at UTSW. bit.ly/3O02s8a #JADPROLive @APSHOorg
Image from UTSW Careers (@UTSWCareers)
2
3
114
Load more